The US Food and Drug Administration gave the green light for use of a drug combination to advanced breast cancer.
Peter A. Kaufman, MD of the Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, said: “This new indication for Faslodex offers another treatment option for women living with HR+, HER2- advanced or metastatic breast cancer with disease progression after endocrine therapy. The study supporting this indication demonstrated that Faslodex used in combination with abemaciclib significantly improves progression-free survival compared to Faslodex and placebo.”
The FDA approval is based on data from a Phase III trial.
This expanded indication for Faslodex is the second FDA approval for Faslodex in combination with a CDK4/6 inhibitor.
Faslodex has been licensed in the US since 2016 for use with the CDK4/6 inhibitor, palbociclib, for the treatment of women with HR+, HER2-negative MBC, whose cancer has progressed after endocrine therapy.
AstraZeneca, at last report, had about 1,500 employees.
